Contineum Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 9.39 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 353.26M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitt...